HLA-B*57:01 Genotyping test HLX HLA Antigen B5701 Case

Synonyms

Allscripts (AEHR) Order Name

HLX HLA B57-01 Antigen Case

Sunrise Clinical Manager (SCM) Order Name

HLX HLA B57-01 Antigen Case

Clinical Info

Hypersensitivity to abacavir has been strongly associated with the HLA-B*57:01 allele. DNA-based testing to assess the presence of HLA-B*57:01 offers higher specificity than serologic testing because monoclonal antibodies may show cross-reactivity with other HLA subtypes. The U.S. Food and Drug Administration (FDA) recommends pre-therapeutic screening for the HLA-B*57:01 allele. Routine screening has been shown to reduce the incidence of ABC HSR from 8% to <0.5% in abacavir-naïve patients. Patients testing positive should not be treated with a regimen containing abacavir.

Specimen Type

Blood

Container

Lavender Top Tube

Collection Instructions

Container/Tube: Lavender Top (EDTA) tube 
Specimen: 1-3 mL of peripheral blood 
Specimens should be accompanied by a test request form and a signed consent form stating that the patient agrees to be tested for HLA-B*5701 genotyping. The consent form should be signed by the patient or designee and the health care provider. 

Transport Instructions

Room Temperature

Specimen Stability

Specimens are stable for a week refrigerated.

Methodology

Real Time Polymerase Chain Reaction (RT-PCR)

Days Performed

Monday through Friday
TAT: 8 Calendar days

Performing Laboratory

Northwell Health Laboratories

CPT

81381

PDM

228468

Result Interpretation

An interpretative report will be provided.

Forms

edit